The average one-year price target for TRACON Pharmaceuticals (NASDAQ:TCON) has been revised to 6.63 / share. This is an increase of 21.88% from the prior estimate of 5.44 dated October 4, 2023. The ...
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...
Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022 “The ENVASARC trial ...
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of ...
San Diego biotech Tracon is lining up for a $57.5 million IPO to bankroll an ambitious program for its lead cancer drug, with major shareholder New Enterprise Associates lighting the way. The company ...
I-Mab, a clinical-stage biopharmaceutical company with U.S. offices in Gaithersburg, Tuesday was awarded an arbitration victory stemming from a $200 million dispute with Tracon Pharmaceuticals over an ...
Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. [Operator Instructions]. During today's call, we will be making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback